What new Medicare GLP-1 coverage means for employers

• Key insight: Discover how Medicare's GLP-1 Bridge pilot could reshape employer healthcare strategies.
• Expert quote: Jeffrey Vogel, Concorde Health — behavioral and lifestyle support must be part of GLP-1 use to sustain results.
• Forward look: The 18-month Medicare pilot signals accelerating GLP-1 coverage expansion employers should prepare for.
  Source: Bullets generated by AI with editorial review

Medicare launched an 18-month pilot program Wednesday called Medicare GLP-1 Bridge, giving eligible participants access to certain GLP-1 medications for $50 per month. While this program is separate from employer-sponsored health plans, benefits that contribute to the long-term success of these prescription drugs may soon be in higher demand. 

With millions of Americans aged 65 and older remaining in the workforce, employers will no doubt see the use of GLP-1s increase among this population. Eligible participants are those enrolled in Medicare drug coverage (Part D) with a body mass index (BMI) of 35 or more, or a slightly lower BMI accompanied by at least one other weight-related condition — for example, someone with a BMI between 27-29.99 who is also diagnosed with prediabetes, according to Medicare.gov.  

"It's certainly good news for Medicare beneficiaries who have been essentially shut out of the market for GLP-1s for weight loss if they wanted to use insurance coverage," said Juliette Cubanski, vice president and director of Medicare policy at nonprofit health care research organization KFF, in an article for the Washington Post. "However, it is a temporary program. It is not a permanent change in Medicare coverage."

Read more:  Organizations forced to rehire managers following AI-driven layoffs

Regardless of their involvement in GLP-1 medication coverage, all employers benefit from a healthier workforce. Those with employees on these medications should assess whether their health and wellness benefits can support those taking GLP-1s in making the necessary lifestyle adjustments to help keep any lost weight off once the medication is stopped — a documented challenge for many.   

In an analysis of 37 studies involving more than 9,000 participants published in the British Medical Journal, people who had taken the most common GLP-1s lost an average of 33 pounds but gained back more than 60% within a year of stopping the medication, said Sam West, a physiology researcher at Oxford University and co-author of the study, in an interview with the Washington Post. Other health improvements like reduced blood pressure and cholesterol also declined.  

If employers want those who use GLP-1 medications to sustain long-term improvements to their health, lifestyle and behavioral support before, during and after their use should be a part of the journey, said Jeffrey Vogel, founder and CEO of Concorde Health, a behavioral governance platform for employer-sponsored GLP-1 programs that offers personalized coaching for employees.   

"The Medicare news is a signal flare: GLP-1 access is expanding fast, and a lot of those newly covered people are somebody's employee," he said. "As usage climbs, the employers who win are the ones who put behavioral and lifestyle support in front of people the day they start the drug, not after they've already drifted." 

Read more:  Managers play a key role in employee mental health, benefits use

'The prescription is the easy part'

Wei-Li Shao, president at Omada Health, echoes the need for expert, structured support alongside GLP-1 use. Omada is a virtual care platform designed to help individuals manage weight-related conditions like prediabetes, type 2 diabetes and musculoskeletal (MSK) issues.  

"The challenge is that the prescription is the easy part," he explained. "Life happens after it's filled, and that is where most of these therapies fall apart. People go on and off the medication. They regain weight. They lose muscle. They run into side effects with no one to call."

When employees are given holistic support that leads to long-term improvements in weight and associated conditions, it's a massive win for employers. The direct healthcare costs related to  individuals who are overweight or obese with associated comorbidities are $480 billion, and lost productivity surpasses $1 trillion, according to nonprofit economic think tank the Milken Institute. 

"Some employers are already requiring members on GLP-1s to enroll in a lifestyle program alongside the medication," says Shao. "The data on those programs is clear: weight stays off, muscle stays on, persistence goes up. Pairing the prescription with structured support is how employers turn an expensive drug into an actual outcome and ROI."

Read more:  Adoption-friendly workplace benefits continue steady climb

No matter where employees are getting access to GLP-1s, it is in employers' best interest to maximize their effectiveness, and they can achieve this by offering benefits that help people look beyond the medication as a permanent weight-loss solution.  

"The medication is the catalyst, not the cure," Vogel said. "These drugs suppress appetite; they don't teach anyone how to eat, move or sleep, and when the prescription stops, the weight comes back unless something else changes in between."